Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02788617 · ClinicalTrials.gov registry record
Evaluation of the Efficacy of Diafert in Predicting Embryos' Potential to Develop to the Blastocyst Stage
A clinical trial, sponsored by Forest Laboratories.
- Completed
- Registry status
- 100
- Enrollment target
NCT02788617: Completed study, sponsored by Forest Laboratories.
NCT02788617 is a clinical trial that has completed, run by Forest Laboratories. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02788617 has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
This prospective study will evaluate the efficacy of Diafert as an adjunct to morphological assessment in predicting embryos' potential to develop to the blastocyst stage on Day 5.
Primary Outcome
The status of each embryo will be assessed by an independent panel of 5 embryologists through visual inspection using the Society for Assisted Reproductive Technology (SART) criteria to determine if each embryo has achieved the blastocyst stage of development or not.
Interventions
- DEVICE Diafert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2016-06-24 |
| Est. Completion | 2017-04-04 |
What the finished NCT02788617 record still lists
NCT02788617 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Diafert is the first listed.
NCT02788617 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02788617 about?
NCT02788617 is a clinical study titled "Evaluation of the Efficacy of Diafert in Predicting Embryos' Potential to Develop to the Blastocyst Stage". This prospective study will evaluate the efficacy of Diafert as an adjunct to morphological assessment in predicting embryos' potential to develop to the blastocyst stage on Day 5.
What is the current status of trial NCT02788617?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2016-06-24. Estimated completion is 2017-04-04.
What interventions are being tested in trial NCT02788617?
The interventions under investigation include: Diafert (DEVICE).
Who is sponsoring clinical trial NCT02788617?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI